Immunomedics (IMMU)
Immunomedics Gross Profit Margin: 90.67%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
IMMU Gross Profit Margin Rankings
| Overall | 95th percentile | 194 of 3917 |
| Sector | 92nd percentile | 27 of 368 in Healthcare |
| Industry | 80th percentile | 14 of 72 in Biotechnology |
IMMU Gross Profit Margin Range, Past 5 Years
| Minimum | 64.20% | Jun 2007 |
| Maximum | 99.81% | Sep 2009 |
| Average | 92.69% |
About Gross Profit Margin
Gross profit margin is the difference between sales and the cost of goods sold divided by revenue. It expresses the relationship between gross profit (sales - cost of goods sold) and sales revenue. More specifically, gross profit margin represents the percentage of each dollar of a company's revenue that is available to cover fixed costs after paying for the goods or services that were sold.
If a company produces widgets and earns $32 million in sales but pays $24 million for the items sold, then the company's gross profit margin would be ($32m - $24m)/$32m = %25.
Learn More
You may also be interested in these IMMU related companies
IMMU News
Immunomedics to Present at Bank of America Merrill Lynch 2012 Health Care Conference
May 10, 8:30AM GlobeNewswire
May 10, 8:30AM GlobeNewswire
Immunomedics Announces Third Quarter Fiscal 2012 Results and Clinical Program Developments
May 08, 4:00PM GlobeNewswire
May 08, 4:00PM GlobeNewswire
Immunomedics Awarded New Patent for Pretargeted Imaging and Therapy of Cancer With Bispecific Antibody
May 01, 8:15AM GlobeNewswire
May 01, 8:15AM GlobeNewswire
Immunomedics Develops Bispecific Hexavalent Antibodies for Diverse Epithelial Cancers
Apr 02, 2:00PM GlobeNewswire
Apr 02, 2:00PM GlobeNewswire
Immunomedics Reports Clinical Results of Pretargeted Radioimmunotherapy of Colorectal Cancer
Apr 02, 9:05AM Benzinga
Apr 02, 9:05AM Benzinga
Immunomedics to Report Progress With Novel DNL Agents Targeting Solid Tumors at Cancer Conference
Mar 26, 8:30AM GlobeNewswire
Mar 26, 8:30AM GlobeNewswire
$IMMU 200 Day SMA Cross - Price crossed below 200 day SMA (3.625). Confirmed by volume.
about 112 days ago by TradeIdeasQuant
about 112 days ago by TradeIdeasQuant
$IMMU in play. looking to break out. remain very bullish on this stock
about 112 days ago by Proptr4d3r
about 112 days ago by Proptr4d3r
RT @Benzinga $IMMU Reports Q2 EPS $0.27 vs $(0.08) Est; Revs $29.7M vs $11.47M Est < uh, what a report here. worth noting.
about 112 days ago by 1nvestor
about 112 days ago by 1nvestor
$IMMU Reports Q2 EPS $0.27 vs $(0.08) Est; Revs $29.7M vs $11.47M Est
about 112 days ago by Benzinga
about 112 days ago by Benzinga
Immunomedics Announces Second Quarter Fiscal 2012 Results and Clinical Program Developments
Feb 08, 8:30AM GlobeNewswire
Feb 08, 8:30AM GlobeNewswire
$IMMU 200 Day SMA Cross - Price crossed below 200 day SMA (3.6239). Confirmed by volume.
about 118 days ago by TradeIdeasQuant
about 118 days ago by TradeIdeasQuant
$immu with a little bit of vol will fly. daily and weekly look great
about 119 days ago by Proptr4d3r
about 119 days ago by Proptr4d3r
also $IMMU is a solid long. like the fundies and char. over the 200ma should run run run
about 119 days ago by Proptr4d3r
about 119 days ago by Proptr4d3r
Immunomedics Awarded Broad Patent for Anti-CD20 and Anti-CD22 Combination Therapy
Jan 31, 8:31AM Benzinga
Jan 31, 8:31AM Benzinga
Oppenheimer Maintains Outperform on Immunomedics After Partnership Restructuring
Dec 28, 12:21PM Benzinga
Dec 28, 12:21PM Benzinga
Immunomedics and UCB Announce Restructuring of Epratuzumab License Agreement
Dec 28, 1:00AM GlobeNewswire
Dec 28, 1:00AM GlobeNewswire
Immunomedics (IMMU) Receives US Patent 8,076,140 for Improved Cell Lines for Protein Therapeutic Manufacturing
Dec 14, 8:37AM Street Insider
Dec 14, 8:37AM Street Insider
Immunomedics Awarded New Patent for Improved Cell Lines for Protein Therapeutic Manufacturing
Dec 14, 8:30AM Benzinga
Dec 14, 8:30AM Benzinga
Immunomedics $IMMU Shares Jump 4% as FDA Lifts Partial Hold on Clivatuzumab Trial
about 210 days ago by Street_Insider
about 210 days ago by Street_Insider
$IMMU filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/oSS
about 217 days ago by MarketBrief
about 217 days ago by MarketBrief
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IMMU | 3.365 | -0.04 | -1.32% | 257.56M |
| IMMR | 5.62 | +0.23 | +4.27% | 150.27M |
| IMKTA | 15.27 | -0.35 | -2.24% | 379.10M |
| IMI | 6.73 | +0.00 | +0.00% | |
| IMH | 2.02 | -0.01 | -0.49% | 15.80M |
| IMGN | 14.32 | -0.14 | -1.00% | 1.111B |
| IMC | 15.21 | -0.07 | -0.47% | |
| IMAX | 21.46 | -0.51 | -2.32% | 1.435B |
| IM | 18.05 | -0.04 | -0.22% | 2.715B |
| ILMN | 44.21 | +0.01 | +0.02% | 5.448B |
